| 2306 |
HALT-Pathologic Underpinnings |
Aloke V. Finn |
May. 08. 23 |
| 2305 |
Should Jardiance be Used as 1st Essential Medication for Heart Failure, Regardless of LVEF? |
Kyung Hoon Cho |
Apr. 20. 23 |
| 2304 |
Jardiance, The First Successful Result for Heart Failure with Preserved Ejection Fraction |
Wonjae Lee |
Apr. 20. 23 |
| 2303 |
My First Impression on using Sentinel Device during TAVI |
Si-Hyuck Kang |
Apr. 20. 23 |
| 2302 |
Why Should We Consider ACURATE neo2 ? - Based on Clinical Evidence |
Jeehoon Kang |
Apr. 20. 23 |
| 2301 |
Introduction to a New TAVI Valve - ACURATE neo2 |
Cheol Woong Yu |
Apr. 20. 23 |
| 2300 |
FFR Pullback Quantification to Guide Intervention: The Ongoing PPG Global Registry |
Nils Johnson |
Apr. 20. 23 |
| 2299 |
CT Guided PCI: A Novel Approach for Imaging Guided Interventions |
Carlos Collet |
Apr. 20. 23 |
| 2298 |
Precision Approaches for Acute Coronary Syndrome Based on OCT-determined Pathogenesis |
Yoshiyasu Minami |
Apr. 20. 23 |
| 2297 |
Role of Angio-based FFR for the Planning of PCI |
Hitoshi Matsuo |
Apr. 20. 23 |
